Ticlopidine

Systematic (IUPAC) name
5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine
Identifiers
CAS number	55142-85-3
ATC code	B01AC05
PubChem	5472
DrugBank	APRD01257
Chemical data
Formula	C14H14ClNS
Mol. mass	263.786 g/mol
Pharmacokinetic data
Bioavailability	>80%
Protein binding	98%
Metabolism	Hepatic
Half life	12 hours (single dose) 4 to 5 days (after repeated dosing)
Excretion	Renal and fecal
Therapeutic considerations
Pregnancy cat.	B1(AU) C(US)
Legal status
Routes	Oral

Ticlopidine (trade name Ticlid) is an antiplatelet drug in the thienopyridine family. Like clopidogrel, it is an adenosine diphosphate (ADP) receptor inhibitor. It is used in patients in whom aspirin is not tolerated, or in whom dual antiplatelet therapy is desirable. Because it has been reported to increase the risk of thrombotic thrombocytopenic purpura (TTP) and neutropenia, its use has largely been supplanted by the newer drug, clopidogrel, which is felt to have a much lower hematologic risk. The usual dose is 250 mg twice daily by the oral route.

[edit] Action

• Inihibits platelet aggregation by altering the function of platelet membranes.
• Prolongs bleeding time.
• Decreased incidence of stroke in high-risk patients.

[edit] Contraindications

• Hypersensitivity
• Bleeding disorders
• Active bleeding
• Severe liver disease

[edit] Precautions

• Risk of bleeding (trauma, surgery, history of peptic ulcer disease)
• Renal or hepatic impairment
• Geriatric patients (increased sensitivity)
• Pregnancy, lactation, or children under 18
• Neutropenia
• Thrombotic thrombocytopenic purpura